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AI for infectious disease modelling and therapeutics is an emerging area that leverages new              
computational approaches and data in this area. Genomics, proteomics, biomedical literature,           
social media, and other resources are proving to be critical tools to help understand and solve                
complicated issues ranging from understanding the process of infection, diagnosis and           
discovery of the precise molecular details, to developing possible interventions and safety            
profiling of possible treatments. 
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1.  Background 
Back in the 19th century, physicians and scientists used to think “bad air” was the source of                 
infection and disease. This miasma theory was ultimately replaced by the germ theory with the               
advance of the microscope and the discovery of microorganisms. This switch dramatically            
changed our understanding of infectious disease and started the new era of public health. This year                
again, the outbreak of novel coronavirus 2019-nCoV has turned people’s attention to the             
importance of surveillance, prevention, diagnosis and treatment of infectious disease. 
  
Besides harmful viruses like the coronavirus (e.g. 2019-nCoV, SARS, MERS), HIV, Zika, Ebola             
virus, some bacteria (1%) cause diseases in people such as tuberculosis (​Mycobacterium            
tuberculosis ​) and pertussis (​Bordetella pertussis ​). While most antibiotic drugs were developed for            
bacteria-based infection, antibiotic resistance has become a growing challenge because of           
antibiotic misuse and poor stewardship. On the other hand, adopting new microbiome-based            
therapeutics is another potential risk delivering antimicrobial resistance genes to the human body             
and intestinal microtome via mobile genetic elements (or the other way around). For example, an               
important safety alert has been issued for use of a recent successful FDA-approved             
microbiome-based intervention, fecal microbiota transplantation (FMT) due to transmission of          
multi-drug resistant organisms. Disordered protein modelling is playing an important role in            
understanding microorganism structure and function as well. 
2.  Introduction 
New computational approaches are leading to new possibilities for AI for infectious disease             
modelling and therapeutics, leveraging new resources such as the 2019-nCoV-released          
genomic sequences along with protein-protein interactions, among others. The large number of            
bacteria, viruses, fungi, and other microorganism genomes that are available along with            
clinical implications of observed mutations, make these particularly amenable to development           
of novel computational methods. By combining information at multiple scales, new insights            
have arisen via the tools, pipelines, and associated algorithm development as well. This             
session has a number of areas that integrated AI for infectious disease modelling and              
therapeutics in the proceedings: 
3.  Social Media and COVID-19  
In “Characterization of Anonymous Physician Perspectives on COVID-19 Using Social Media           
Data” by K. J. Sullivan, et. al. [1] explored using Twitter to characterize different perspectives on                
COVID-19. Specifically, physician direct messages were compared to general public tweaks.           
The work analyzed over 513 million tweets in the process. Sentiment and n-gram analysis              
revealed patterns within physician vs public discourse regarding COVID-19​1​. 
4.  Biomedical literature and COVID-19 plus neglected tropical diseases 
Work by B. Dinakar, et. al. [2] explored the biomedical literature using an algorithm to find novel                 
directions in disease research, with focus on COVID-19 and also neglected tropical diseases. The              
paper “Semantic Changepoint Detection for Finding Potentially Novel Research Publications”          

























































































analyzed publications over time to find patterns where there are significant changes in direction              
such that a semantic changepoint can be defined by the algorithm. The software is also released                
via link in the paper. 
5.   Genomics and HCV 
S. Sledzieski, et. al. [3] describe a new method for reconstructing transmission phylogenies that              
increases accuracy while maintaining scalability. The paper “TreeFix-TP: Phylogenetic         
Error-Correction for Infectious Disease Transmission Network Inference” applied the method to           
HCV outbreaks.  It also released the software via link in the paper. 
6.   Protein intrinsically disordered regions and SARS-CoV-2 
A. Mudide, et. al. [4] analyzed SARS-CoV-2 for certain protein regions, known intrinsically             
disordered regions, that have additional flexibility, that may be targets for drug candidates. The              
paper, “SARS-CoV-2 Drug Discovery Based On Intrinsically Disordered Regions,” also leveraged           
different docking approaches to model this flexibility and prioritize potential drug candidates,            
analyzing over 290 thousand compounds. 
  
G. Goh, et. al. [5] analyzed the shell disorder of SARS-CoV-2 and other viruses to establish shell                 
disorder as a proxy for vaccine development feasibility. It characterized SARS-CoV-2 as having             
an exceptionally hard outer shell, suggesting that vaccine development for SARS-CoV-2 is likely             
feasible and may be easier than for several other viruses such as HIV, HSV and HCV. The work in                   
the paper “Feasibility study of vaccine development for SARS-CoV-2 and other viruses using             
shell disorder analysis” also presented several ideas on how shell disorder can be leveraged to               
characterize virulence, immune system evasion, and potential animal hosts.  
7.  Protein-protein interactions and SARS-CoV-2 
M. Kshirsagar, et. al. [6] examined protein-protein interactions between viruses and their host. By              
comparing SARS-CoV-2 and host interactions with other virus-host interactions a number of            
motifs and themes emerged. The paper, entitled, “Functional comparison of virus-host pathogen            
communication using sequence-feature based SARS-CoV-2 protein interaction prediction” also         
specifically created SARS-CoV-2-human protein-protein interaction predictor based on sequence         
information and validated it with an independent dataset. 
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